Lausanne-headquartered Swiss biotechnology firm SwissNovaGene has announced its entry into the sports nutrition sector with the launch of MOVE, an eight-formula range of micronutrient supplements.
The biotech company notes that MOVE is engineered around 15 years of human clinical research. Previously restricted to private Swiss clinical settings, the formulations are now being made available directly to athletes, coaches, and performance professionals.
Manufactured in Switzerland, the product line is built around combinatorial micronutrition – the strategic pairing of microdosed vitamins, minerals, botanicals, and algae. SwissNovaGene adds that this is designed to act synergistically on specific physiological processes, offering an alternative to conventional high-dose, single-nutrient supplementation.
Specialized Formulations Across Recovery and Mobility Pillars
The MOVE product ecosystem is structured into two distinct product pillars that are designed to support cellular function, metabolic pathways, and structural durability:
- Recovery & Performance Pillar: Features five specialised formulations targeting daily adaptation and recovery. These include MOVE Sleep (formulated to improve sleep quality), MOVE Stress (designed for cognitive clarity and stress management without sedation), MOVE Metabolism (focused on cellular energy production), MOVE Detox (supporting natural metabolic pathways), and MOVE Immunity (supporting immune resilience during heavy training and travel blocks).
- Mobility & Structural Integrity Pillar: Features three targeted products for tissue stress and mechanical loading. These include MOVE Joints (supporting cartilage and connective tissue health), MOVE Muscles & Tendons (focusing on structural tissue integrity), and MOVE Circulation (designed to optimize fluid exchange and relieve leg heaviness following heavy training).
Clinical Research Portfolio
SwissNovaGene underlines that its underlying formulations are backed by 15 years of human clinical research, including randomised, double-blind trials evaluating sleep, stress regulation, immune function, and lipid metabolism.
Published company-reported data highlights include:
- MOVE Sleep: A 42% reported reduction in sleep disorder scores measured via EEG assessments over a four-week period in a 160-participant randomised trial.
- MOVE Stress: Resolution of reported stress symptoms in 65.4% of participants over an eight-week period in a 158-participant randomised trial.
The MOVE range features a micro-pearl delivery format. Capsules are designed to be opened so the micro-pearls can dissolve directly on the tongue, accelerating absorption while establishing a distinct consumer product experience.
Dominique Weill, Founder and CEO of SwissNovaGene, said “At SwissNovaGene, we believe that the future of sports nutrition lies in a deeper understanding of human biology. For many years, the industry has focused primarily on energy, protein and individual nutrients. These remain important elements of athletic nutrition, but they represent only part of the picture.
“The ability to perform consistently also depends on sleep, stress regulation, metabolic balance, immune resilience and the integrity of joints, muscles and connective tissues.”
Weill added “Our ambition with MOVE was to translate 15 years of research in combinatorial micronutrition into a new generation of nutritional solutions for athletes and performance professionals. We believe that intelligently combining natural micronutrients, in carefully developed proportions, offers an interesting new direction for nutritional science and its practical application.
“MOVE represents our commitment to bringing this philosophy, developed through Swiss research and innovation, to a broader international community.”











